Literature DB >> 15495033

Prophylactic mastectomy for the prevention of breast cancer.

L Lostumbo1, N Carbine, J Wallace, J Ezzo.   

Abstract

BACKGROUND: Breast cancer is the most common cancer and the second most common cause of cancer-related death among North American and Western European women. Recent progress in understanding the genetic basis of breast cancer, along with rising incidence rates, have resulted in increased interest in prophylactic mastectomy as a method of preventing breast cancer, particularly in those with familial susceptibility.
OBJECTIVES: The primary objective was to determine whether prophylactic mastectomy reduces death from any cause in women who have never had breast cancer and in women who have a history of breast cancer in one breast. The secondary objective was to examine the effect of prophylactic mastectomy on other endpoints including breast cancer incidence, breast cancer mortality, disease-free survival, physical morbidity, and psychosocial outcomes. SEARCH STRATEGY: Electronic searches were performed in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Cancerlit, and the Science Citation Index. SELECTION CRITERIA: Inclusion criteria were studies in English of any design type including randomized or nonrandomized controlled trials, cohort studies, case-control studies, and case series with at least ten participants. Participants included women at risk for breast cancer in at least one breast. Interventions included all types of mastectomy performed for the purpose of preventing breast cancer, including subcutaneous mastectomy, total or simple mastectomy, modified radical mastectomy, and radical mastectomy. DATA COLLECTION AND ANALYSIS: Information on patients, interventions, methods, and results were extracted by at least two independent reviewers. Methodological quality was assessed based on how well each study minimized potential selection bias, performance bias, detection bias, and attrition bias. Data for each study were summarized descriptively; quantitative meta-analysis was not feasible due to heterogeneity of study designs and insufficient reporting. Data were analyzed separately for bilateral prophylactic mastectomy (BPM) and contralateral prophylactic mastectomy (CPM). MAIN
RESULTS: Twenty-three studies, including more than 4,000 patients, met inclusion criteria. No randomized or nonrandomized controlled trials were found. Most studies were either case series or cohort studies. All studies had methodological limitations, with the most common source of potential bias being systematic differences between the intervention and comparison groups that could potentially be associated with a particular outcome. Thirteen studies assessed the effectiveness of BPM. No study assessed all-cause mortality after BPM. All studies reporting on incidence of breast cancer and disease-specific mortality reported reductions after BPM. Nine studies assessed psychosocial measures; most reported high levels of satisfaction with the decision to have prophylactic mastectomy (PM) but more variable satisfaction with cosmetic results. Only one study assessed satisfaction with the psychological support provided by healthcare personnel during risk counseling and showed that more women were dissatisfied than satisfied with the support they received in the healthcare setting. Worry over breast cancer was significantly reduced after BPM when compared both to baseline worry levels and to the groups who opted for surveillance rather than BPM. Three studies reported body image/feelings of femininity outcomes, and all reported that a substantial minority (about 20%) reported BPM had adverse effects on those domains. Six studies assessed contralateral prophylactic mastectomy. Studies consistently reported reductions in contralateral incidence of breast cancer but were inconsistent about improvements in disease-specific survival. Only one study attempted to control for multiple differences between intervention groups, and this study showed no overall survival advantage for CPM at 15 years. Two case series were exclusively focused on adverse events from prophylactic mastectomy with reconstruction, and both reported rates of unanticipated re-operations from 30% to 49%. REVIEWERS'
CONCLUSIONS: While published observational studies demonstrated that BPM was effective in reducing both the incidence of, and death from, breast cancer, more rigorous prospective studies (ideally randomized trials) are needed. The studies need to be of sufficient duration and make better attempts to control for selection biases to arrive at better estimates of risk reduction. The state of the science is far from exact in predicting who will get or who will die from breast cancer. By one estimate, most of the women deemed high risk by family history (but not necessarily BRCA 1 or 2 mutation carriers) who underwent these procedures would not have died from breast cancer, even without prophylactic surgery. Therefore, women need to understand that this procedure should be considered only among those at very high risk of the disease. For women who had already been diagnosed with a primary tumor, the data were particularly lacking for indications for contralateral prophylactic mastectomy. While it appeared that contralateral mastectomy may reduce the incidence of cancer in the contralateral breast, there was insufficient evidence about whether, and for whom, CPM actually improved survival. Physical morbidity is not uncommon following PM, and many women underwent unanticipated re-operations (usually due to problems with reconstruction); however, these data need to be updated to reflect changes in surgical procedures and reconstruction. Regarding psychosocial outcomes, women generally reported satisfaction with their decisions to have PM but reported satisfaction less consistently for cosmetic outcomes, with diminished satisfaction often due to surgical complications. Therefore, physical morbidity and post-operative surgical complications were areas that should be considered when deciding about PM. With regard to emotional well-being, most women recovered well postoperatively, reporting reduced cancer worry and showing reduced psychological morbidity from their baseline measures; exceptions also have been noted. Of the psychosocial outcomes measured, body image and feelings of femininity were the most adversely affected.

Entities:  

Mesh:

Year:  2004        PMID: 15495033     DOI: 10.1002/14651858.CD002748.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  37 in total

Review 1.  United States trends in the surgical treatment of primary breast cancer.

Authors:  Todd M Tuttle; Natasha M Rueth; Andrea Abbott; Beth A Virnig
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

Review 2.  The role of BRCA mutation testing in determining breast cancer therapy.

Authors:  Alison H Trainer; Craig R Lewis; Kathy Tucker; Bettina Meiser; Michael Friedlander; Robyn L Ward
Journal:  Nat Rev Clin Oncol       Date:  2010-11-09       Impact factor: 66.675

3.  Trachoma, antibiotics and randomised controlled trials.

Authors:  B Shapiro; K Dickersin; T Lietman
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

4.  Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group.

Authors:  Regina Kroiss; V Winkler; K Kalteis; D Bikas; M Rudas; M Tea; C Fuerhauser; D Muhr; H Cerny; S Glueck; E Petru; H Concin; E Kubista; P Oefner; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-08       Impact factor: 4.553

5.  Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial.

Authors:  Jennifer Livaudais-Toman; Leah S Karliner; Jeffrey A Tice; Karla Kerlikowske; Steven Gregorich; Eliseo J Pérez-Stable; Rena J Pasick; Alice Chen; Jessica Quinn; Celia P Kaplan
Journal:  Breast       Date:  2015-10-21       Impact factor: 4.380

6.  Breast cancer: why do women opt for contralateral prophylactic mastectomy?

Authors:  Aron Goldhirsch; Shari Gelber
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

7.  Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer.

Authors:  Patricia A Parker; Susan K Peterson; Isabelle Bedrosian; Melissa A Crosby; Yu Shen; Dalliah M Black; Gildy Babiera; Henry M Kuerer; Jun Ying; Wenli Dong; Scott B Cantor; Abenaa M Brewster
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

8.  Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.

Authors:  Laura H Rosenberger; Ryan Weber; Daniel Sjoberg; Andrew J Vickers; Debra A Mangino; Monica Morrow; Melissa L Pilewskie
Journal:  Breast Cancer Res Treat       Date:  2017-01-28       Impact factor: 4.872

Review 9.  The increasing use of prophylactic mastectomy in the prevention of breast cancer.

Authors:  Todd M Tuttle; Andrea Abbott; Amanda Arrington; Natasha Rueth
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

10.  Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Authors:  Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.